Novo Nordisk's Uphill Battle: Better Guidance, But a Pipeline That Won't Cooperate

Novo Nordisk raises 2026 guidance but shares fall 12.8% on weak oral Wegovy sales and pipeline setbacks, including Monlunabant impairment.

Investors have a peculiar habit of punishing good news when it arrives wrapped in bad. Novo Nordisk's latest week is a textbook case: the Danish pharma giant raised its 2026 outlook, posted respectable second-quarter growth, and still watched its shares get pummeled. The stock has now shed 12.83 percent over seven trading sessions, and even Wednesday's 2.45 percent bounce to 39.33 euros in Frankfurt does little to mask the underlying unease.

The numbers themselves tell a story of operational resilience. Adjusted revenue for the second quarter reached 78.488 billion Danish kroner, up 7 percent at constant exchange rates, while adjusted operating profit climbed 11 percent to 33.389 billion kroner. Management now guides for adjusted revenue growth of between 0 and minus 6 percent for the full year at constant currencies — a meaningful improvement over the previous forecast, which contemplated a decline of up to 12 percent. The operating profit outlook follows the same pattern: 0 to minus 6 percent instead of a potential 12 percent drop.

Yet the headline figures conceal a deeper problem. Reported operating profit tumbled 16 percent, dragged down by a non-cash impairment of 6.3 billion kroner, including 4.0 billion kroner written off against the pipeline candidate Monlunabant. That charge, combined with a pipeline that keeps misfiring, has eroded the narrative that once made Novo Nordisk a market darling.

The Pill That Was Supposed to Change Everything

The oral Wegovy formulation has long been positioned as the natural evolution of the company's weight-loss franchise — the logical bridge from injection to tablet. But the pill's second-quarter sales of 3.22 billion kroner came in just shy of the 3.27 billion kroner consensus, and Mizuho analyst Jared Holz captured the market's mood on Tuesday when he called the guidance raise "clearly not heroic." The absence of an upside surprise in pill sales, he noted, weighed on sentiment.

There is some progress on the commercial front. Following European Union approval on July 15, Italy has been confirmed as the first EU market to launch the oral tablet, with Germany expected to follow in the third quarter with the 25-mg once-daily version. But these are incremental wins in a battle that has become existential for the company's growth story.

The pipeline setbacks extend beyond Monlunabant. CagriSema, once positioned as the next-generation therapy for obesity, disappointed in clinical studies, forcing management to acknowledge that its internal research engine alone may no longer suffice. Chief executive Mike Doustdar has pledged to accelerate research efforts and is actively evaluating several bolt-on acquisitions to rebuild the pipeline — an admission, in effect, that organic development is no longer delivering at the pace investors expect.

A Failed Trial and a Legal Victory

The cardiovascular program has also hit turbulence. The Phase 3 ZEUS study of Ziltivekimab failed to meet its primary endpoint of reducing major adverse cardiovascular events, despite demonstrating the expected inhibition of the IL-6 pathway. Morningstar analyst Karen Andersen removed the candidate from her model on Monday but left her fair value estimate for the company unchanged — a small signal that not every setback upends the entire valuation thesis.

On the legal front, Novo Nordisk secured a win in the Netherlands on Wednesday, obtaining a preliminary injunction against Ceban Ziekenhuisfarmacie B.V. over its compounded semaglutide nasal spray. The court order halts distribution of the infringing product, adding to the company's broader campaign against copycat versions of its blockbuster medicines.

Buybacks, Skeptics, and the Long Road Back

Management continues to signal confidence through share repurchases. Between July 27 and August 3, Novo Nordisk bought back 1,145,000 B-shares for 370.9 million kroner, bringing its treasury stock to 44,249,480 shares — roughly 1.0 percent of share capital. The cumulative buyback program now stands at 12,305,000 B-shares for 3.73 billion kroner.

Not everyone is convinced. Lazard Asset Management trimmed its position in Novo Nordisk ADRs on Sunday, and Jefferies reaffirmed its "Hold" rating with a 285 kroner price target after the earnings release — a stance that reflects neither panic nor enthusiasm.

The stock's distance from its 52-week high of 54.86 euros, set in late January, now stands at roughly 28.76 percent. A relative strength index of 37.2 suggests the shares are technically oversold, though such indicators offer limited insight into the fundamental questions at hand. Citigroup, for its part, had the stock rated "Neutral" as of July 29, before the results were published.

The real test comes later. Novo Nordisk hosts its Capital Markets Day on September 20-21, followed by nine-month results on November 4. Between now and then, the market will be watching whether the company can articulate a credible path forward — one that addresses not just the immediate guidance shortfall, but the deeper question of who will lead the next generation of obesity treatments. The company that created the category is still in the race, but the finish line has never looked further away.